



## ampli set FV<sup>CE IVD</sup>

45 tests

cat 1311

detection of A1691G polymorphism of the factor V gene.

A point mutation (substitution A-G) in the position 1691 of the gene encoding for the coagulation factor has been linked to the resistance to the degradation of activated Protein C(1-4). This functional alteration can be correlated to an increased venous thrombotic risk. The functional assay of rAPC (resistance to activated Protein C) is based on the detection of aPTT in plasma of patient with and without a fixed concentration of activated Protein C. This assay is affected by a lot of factors, as citrate used as anticoagulative, calcium chloride, the kind of activator, the purity of activated protein C. Reduced levels of F II and X can distort the results( false normal results). It is impossible to perform the functional assay of activated Protein C during the oral anticoagulant therapy(5), so only the genetic analysis of DNA allows to detect the mutation.

The resistance to activated Protein C is a dominant autosomal transmission.

The mutation in heterozygosis is linked to an increase of 5-10% of thrombotic risk, whereas homozygosis is joined to an increase of 50%. The detection of mutation G1691a is carried out using the PCR amplification method with specific primers for the exon 10 of a fragment of 287 bp, followed by restriction section due to MnlI enzyme. The loss of a restriction cleavage means the presence of the mutation. **The allele 1691G produces fragments of 37, 93 e 157 bp, whereas the allele 1691A produces two fragments of 130 and 157 bp.**


**Principle of method:** A) extraction of genomic DNA; B) amplification; C) enzymatic digestion; D) detection on agarose gel

**Applicability:** on extracted and purified genomic DNA from whole blood samples.

### ANALYSIS OF RESULTS

The yield of amplification is a fragment of 287 bp. The next restriction section made by the MnlI enzyme can be done the following results:

| 1   | 2   | 3   |
|---|---|---|
| Absence of mutation<br>Homozygous Normal<br>Patient | Presence of mutation<br>Eterozygote Mutant<br>patient | Presence of<br>mutation<br>Homozygote mutant<br>patient |
| Presence of 3 lanes                                 | Presence of 4 lanes                                   | Presence of 2 lanes                                     |
| 157 bp<br>93 bp<br>37 bp                            | 157 bp<br>130 bp<br>93 bp<br>37 bp                    | 157 bp<br>130 bp  |



### REFERENCES

- Dahlback B., Hildebrand B. *P.N.A.S.* 1994;91:1396-400.
- Bertina RM et al. *Nature* 1994;369:64-7.
- Voorberg J., et al. *Lancet* 1994;343:1535-36
- Zoller B., et al. *Lancet* 1994;343:1536-38.
- Dahlback B., *Thromb. And Hemost.* 1995;73:739-42.
- Roger M., et al. *Letter to Nature* 1994,369:64-67.
- Beuchamp N.J., et al. *British Journal of Ematology* 1994,88:219-222